Loading...
•
Jun 30, 2021
Day One Q2 2021 Earnings Report
Announced financial results for the second quarter of 2021 and highlighted recent corporate achievements.
Key Takeaways
Day One Biopharmaceuticals reported a net loss of $15.5 million for the second quarter of 2021. The company's cash and cash equivalents totaled $310.0 million as of June 30, 2021, which is expected to fund operations into the second half of 2023.
Dosed the first patients in pivotal FIREFLY-1 clinical trial of DAY101 in patients with pLGG.
Granted Rare Pediatric Disease Designation from FDA.
Granted Orphan Designation from European Commission.
Successfully completed $184 million upsized initial public offering.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...